Dean G. Tsarwhas

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

C. Nabhan, S. Newman, J. Bitran, 2009, Urology.

Medical Oncology Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

C. Nabhan, S. Newman, J. Bitran, 2009 .